Portable Ultrasound Maker Echoes 70% Higher on Compliance Win

A fast-food giant is losing its sizzle as its U.S. sales slide, an automobile giant is slashing its profit outlook due to mounting tariff pressures, and a portable ultrasound startup is soaring 65% after securing a crucial listing compliance win. Here’s what you need to know.

Crypto Uplist Watch (Sponsored)

This Quiet Crypto Player Is About to Make Noise

While most crypto stocks chase hype, this one delivers real results—$144 million in revenue and over $80 million in EBITDA last year.

Now, it’s filed a Form 40 with the SEC, setting the stage for a potential uplisting.

May 1st could change everything.

A profitable Bitcoin infrastructure company—still trading under the radar—may finally step into the spotlight.

Get the full story before the rest of the market catches up.

(By clicking the link above, you agree to receive emails from Huge Alerts. You can opt out at any time. - Privacy Policy)

Futures 📈

What to Watch

Earnings:

• Eli Lilly and Company [LLY]: Premarket

• Mastercard Incorporated [MA]: Premarket

• McDonald’s Corporation [MCD]: Premarket

• KKR & Co. Inc. [KKR]: Premarket

• Linde plc [LIN]: Premarket

• Apple Inc. [AAPL]: Aftermarket

• Amazon.com, Inc. [AMZN]: Aftermarket

• Amgen Inc. [AMGN]: Aftermarket

• Stryker Corporation [SYK]: Aftermarket

• MicroStrategy Incorporated [MSTR]: Aftermarket

Economic Reports:

• Initial Jobless Claims: 8:30 am

• S&P Final U.S. Manufacturing PMI [April]: 9:45 am

• ISM Manufacturing [April]: 10:00 am

• Construction Spending [March]: 10:00 am

Long-Term Wealth Builders (Sponsored)

This Simple List Could Be the Smartest Move You Make in 2025

Some stocks are built to trade. Others are built to last.

This free report reveals 7 companies that have stood the test of time—delivering consistent growth, reliable dividends, and strong balance sheets through bull and bear markets alike.

If you’re looking to build long-term wealth with less stress, this is a great place to start.

Download the 7 Stocks to Buy and Hold Forever Here

(By clicking any of the links above, you will get this free report and a free subscription to MarketBeat's daily email newsletter. You are also agreeing to the terms of our privacy policy.)

Fast Food

Weak First-Quarter Results Weigh on McDonald’s Shares

McDonald’s (NYSE: MCD) stock is down in premarket trade today following a disappointing quarterly earnings release that revealed weaker-than-expected revenue and same-store sales.

The fast-food chain posted adjusted earnings of $2.67 per share, in line with expectations.

However, its revenue is down 3% year-over-year to $5.96 billion—falling short of the $6.12 billion analysts had anticipated.

Comparable sales globally declined by 1%, missing the modest 0.31% growth forecasted. The company noted sales were mostly unchanged when adjusting for last year's Leap Day.

In the U.S. market, however, comparable sales slid 3.6%, underperforming the 1.37% drop expected by Wall Street.

The stock is down 1.2% in premarket trading following the results. Despite the setback, McDonald’s has climbed 10% year-to-date.

Last quarter marked a brief rebound in global same-store sales after two periods of decline, but domestic figures continued to struggle—still feeling the effects of reduced customer traffic linked to a foodborne illness incident last October.

The report casts fresh doubt on the company’s momentum in its core U.S. market heading into the rest of 2025.

Automobiles

GM Revises Profit Forecast, Citing Up to $5 Billion in Trade Costs Due to Tariffs

General Motors (NYSE: GM) trimmed its 2025 profit outlook today, citing financial strain from recent tariff changes that could cost the company as much as $5 billion.

The updated guidance came shortly after the automaker withdrew a previous forecast that didn’t account for the latest trade policy shifts.

In a message to shareholders, CEO Mary Barra said the company remains in close communication with the White House and global trade partners as negotiations continue to evolve.

GM now expects its full-year adjusted operating income to fall between $10 billion and $12.5 billion. That’s a notable cut from its earlier range of $13.7 billion to $15.7 billion.

The estimated net income for the year was also lowered to between $8.2 billion and $10.1 billion, down from $11.2 billion to $12.5 billion.

The tariff-related impact alone is projected to range between $4 billion and $5 billion.

This revision comes amid broader uncertainty surrounding U.S. trade policy under the Trump administration and its implications for the automotive industry.

Shares of GM are down 3.6% on Thursday following the announcement.

High-Grade Resource (Sponsored)

On Behalf of Abitibi Metals

Copper is climbing again—and this time, it looks tariff-proof.

A $31M junior just posted nearly 1B lbs of copper equivalent. 

With insiders and institutions piling in, this could be the next breakout.

Full details here.

*SGS Canada Inc. is responsible for the Technical Report. The Qualified Persons (“QPs”), as defined under NI 43-101, are Yann Camus, P.Eng., and Olivier Vadnais-Leblanc, P.Geo.

Pharmaceuticals

Eli Lilly Trims Outlook After Zepbound Sales Disappoint

Eli Lilly (NYSE: LLY) is seeing its stock drop 4.33% in premarket trading today after revenue from its high-profile weight-loss drug Zepbound slightly missed forecasts, despite an otherwise strong quarterly performance.

Zepbound brought in $2.31 billion in sales for the first quarter, narrowly missing analyst expectations of $2.33 billion, according to LSEG data.

The pharmaceutical company attributed the shortfall to recent price reductions, even as demand remained solid.

In February, the company lowered the monthly price of its lowest Zepbound doses to $349 and $499 while expanding dose availability online.

Adding to the pressure, CVS Health announced it would no longer list Zepbound as a preferred treatment for insurance reimbursement starting July 1, though it will continue covering competitor Novo Nordisk’s Wegovy.

Total revenue for the quarter reached $12.73 billion, slightly beating projections of $12.67 billion. Adjusted earnings landed at $3.34 per share, outpacing the $3.02 analysts had forecast.

Sales of diabetes treatment Mounjaro also exceeded expectations, totaling $3.84 billion versus the projected $3.80 billion.

Despite the solid earnings beat, Eli Lilly lowered its full-year adjusted profit guidance to a range of $20.78 to $22.28 per share, down from its earlier projection.

NanoVibronix, Inc. [NAOV] - Last Close: $2.86

NanoVibronix, Inc. is a medical device company specializing in noninvasive, portable ultrasound-based therapeutic devices. The company grew 12% in revenue last year while reducing net losses by 0.2%. ​

The stock is experiencing nearly 70% growth in premarket trading today after the company's recent announcement of regaining compliance with Nasdaq's listing requirements, alleviating delisting concerns and providing a stable foundation for future growth.​

Interactive Strength Inc. [TRNR] - Last Close: $0.65

Interactive Strength Inc. specializes in innovative specialty fitness equipment and digital fitness services under the CLMBR and FORME brands. In 2024, it reported a 459% year-over-year revenue increase to $5.4 million, while reducing net losses by 32% to $34.9 million. ​

The stock is experiencing a 21% uptick in premarket trading, due to the company's shareholder update confirming that its planned acquisitions are on track and reiterating 2025 pro forma revenue guidance of over $65 million. ​

Haverty Furniture Companies, Inc. [HVT] - Last Close: $18.16

Haverty Furniture is a U.S.-based retailer specializing in residential furniture. The firm has seen declining revenue and earnings, reflecting challenges in the housing market and consumer spending. Its stock is also down 19% YTD.

However, it is rising nearly 10% in premarket trade today after reporting a 58.33% growth in its Q1 net income, despite a drop in revenues.

Uranium Demand (Sponsored)

On Behalf of Azincourt Energy Corp

Why Uranium’s Next Cycle Could Be Bigger Than 2007

With AI pushing power demand through the roof, nuclear is the only option.

Uranium demand is set to double. One junior may benefit most.

Tap here to unlock the name.

*Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT stock recommendations or constitute an offer or sale of the referenced securities.

Everything Else

• CVS outpaces expectations with a strong Q1 and a bold move in the GLP-1 drug market.

• KKR’s global footprint and retail push help drive a billion-dollar quarter.

• Air Products trims earnings guidance after a surprise $2.3B charge and falling demand.

• Microsoft defies economic headwinds with cloud growth and multi-billion dollar quarterly profit.

• Meta brushes off ad jitters with a surprise earnings jump and bullish forecast.

• Investors are rattled as Qualcomm warns of a muted Q3 on rising global trade tensions.

• Despite robust Q3 performance, investor doubts cloud KLA’s future growth path.

• Equinix posts steady revenue growth as demand for digital infrastructure holds firm.

• Aflac stumbles slightly in Q1 as revenue and earnings fall short of Wall Street targets.

That’s all for today. Thank you for reading. If you have any feedback, please reply to this email.

Best Regards,

— Adam Garcia
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.

*Standard message/carrier rates may apply.

Legal Stuff: Stocks featured in this newsletter are for entertainment purposes only. You should not base any investment decisions on information contained in my newsletter. Stocks featured in this newsletter may be owned by owners/operators of this website, which could impact our ability to remain unbiased. Please consult a financial advisor before making any trading decisions. I may earn a small commission from links placed inside these emails.